Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms B-R-ENDA; BRENDA
- 12 Oct 2018 Status changed from recruiting to completed.
- 28 Nov 2015 Planned number of patients changed from 100 to 77, according to European Clinical Trials Database record.
- 07 Sep 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2010-024004-98).